The influence of human papillomavirus type and HIV status on the lymphomononuclear cell profile in patients with cervical intraepithelial lesions of different severity.
BACKGROUND
Immunological alterations are implicated in the increased prevalence of high-grade squamous intraepithelial lesions (HG-SIL) and persistent human papillomavirus (HPV) infection. This study evaluated the expression of CD4, CD8, CD25 (IL-2Ralpha) and CD28 antigens from SIL biopsies, stratified by HIV status and HPV-type. Biopsies specimens from 82 (35 HIV+) women with a normal cervix, low-grade (LG-SIL) or high-grade lesions (HG-SIL) were studied. CD molecule expression was evaluated by immunohistochemistry and HPV detection/typing performed using PCR techniques.


RESULTS
CD4 stromal staining was increased in patients with HPV18. Women with HPV16 infection showed decreased: a) CD8 and CD25 stromal staining, b) CD25 staining in LG-SIL epithelium and in HG-SIL stroma. In HIV- women samples, CD28 epithelial staining and CD8 stromal staining surrounding metaplastic epithelium were less intense and even absent, as compared to HIV+ women. Both epithelial and stromal CD8 staining was more intense in the HG-SIL/HIV+ group than in the HG-SIL/HIV- group. Positive correlations were observed between CD4/CD25, CD4/CD28 and CD25/CD28 in the stroma and CD25/CD28 in the epithelium.


CONCLUSIONS
HIV status and HPV-type may influence the lymphomononuclear cell profile present in the spectrum of cervical lesions. The knowledge of the infiltrating cell profile in cervical tumours may help the development of specific anti-tumoural strategies.
Gonçalves
Maria Alice G
MA
Division of Clinical Immunology, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. epigin@uol.com.br
Soares
Edson G
EG
Donadi
Eduardo A
EA
Genes Dev. 1998 Jul 1;12(13):2061-72
9649509
Science. 1988 Jan 29;239(4839):487-91
2448875
Immunol Today. 1997 Oct;18(10):493-7
9357142
Eur J Obstet Gynecol Reprod Biol. 2004 Jun 15;114(2):221-7
15140519
Clin Exp Immunol. 1998 Aug;113(2):183-9
9717966
Oncogene. 2000 Jan 27;19(4):514-25
10698521
Lab Invest. 1988 Feb;58(2):141-9
2448545
Clin Exp Immunol. 1999 Apr;116(1):33-40
10209502
Hum Immunol. 1997 Aug-Sep;56(1-2):39-48
9455492
Cancer. 1995 Oct 15;76(8):1411-5
8620416
Cancer. 2001 Apr 25;93(2):111-4
11309776
Immunotechnology. 1996 Nov;2(4):241-51
9373306
Cytokine. 1995 Aug;7(6):568-74
8580374
Int J Cancer. 2002 Feb 10;97(5):654-9
11807793
Int J Cancer. 1994 Feb 1;56(3):314-9
8314316
Scand J Immunol. 2002 Aug;56(2):204-11
12121440
Cancer. 1999 Oct 15;86(8):1537-43
10526283
Ciba Found Symp. 1994;187:21-32; discussion 32-44
7796671
Ann Biol Clin (Paris). 1998 May-Jun;56(3):267-76
9754259
Cancer Res. 1996 Sep 1;56(17):3967-74
8752165
Gynecol Oncol. 2000 Mar;76(3):315-9
10684703
J Immunol. 1994 Jul 1;153(1):412-20
7515928
Oncogene. 2000 Jul 6;19(29):3235-44
10918580
J Pathol. 1998 Mar;184(3):283-90
9614381
Cancer Res. 1998 Apr 15;58(8):1700-6
9563486
J Gen Virol. 1996 Jul;77 ( Pt 7):1585-93
8758003
Biotechniques. 1994 Nov;17(5):914-21
7840973
Diagn Mol Pathol. 1996 Sep;5(3):220-4
8866237
Cancer Res. 1994 Dec 1;54(23):6243-8
7954473
Int J Cancer. 2000 Oct 1;88(1):92-8
10962445
J Immunol. 2001 Sep 1;167(5):2972-8
11509647
Curr Opin Obstet Gynecol. 2009 Feb;21(1):54-9
19125004
J Gen Virol. 1990 Jan;71 ( Pt 1):173-81
2154534
Clin Exp Immunol. 1997 Mar;107(3):440-7
9067514
Int J Cancer. 1994 Oct 15;59(2):225-34
7523315
J Pathol. 1999 Sep;189(1):12-9
10451482
J Immunol. 1999 Dec 15;163(12):6762-8
10586075
Int J Cancer. 1994 Jun 15;57(6):805-13
8206676